| Name | Title | Contact Details |
|---|---|---|
Volkmar Weckesser |
Chief Information Officer | Profile |
Formycon ist ein führender und unabhängiger Entwickler von qualitativ hochwertigen biopharmazeutischen Nachfolgeprodukten, sogenannten Biosimilars.
Predictive Biosciences is an innovative developer of molecular diagnostic tests for cancer diagnosis and monitoring. We are focused on understanding and meeting the needs of physicians by providing valuable diagnostic services and laboratory solutions.
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology`s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic.
Life Biosciences was co-founded in 2017 by David Sinclair, PhD, a professor in the Department of Genetics at Harvard Medical School, and Tristan Edwards, who developed its innovative structure as Chapter Two in his life, after a highly successful career as a global institutional investor, working across all asset classes. The company`s novel Daughter company business model creates the robust research ecosystem required to forge industry leadership through two investment strategies. The first is to establish new companies, thereby extending the research of visionary scientists around the world. Secondly, Life Biosciences invests in other groundbreaking firms, providing them with the resources to maximize their potential. In addition to Lua, there are six Daughter companies working independently and together within the Life Biosciences research environment. The company provides Daughter companies with the resources required to maximize human potential, including Lua`s AI-driven data and communications platform, experienced management, drug development experience, and a 25,000 square foot, state-of-the-art vivarium, robotics and drug screening facility in Cambridge, Mass, augmented by laboratories and offices on four continents. Co-founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences is the first and largest biotech company addressing the eight pathways of age-related decline (ARD) in totality. It has established Daughter companies around the world, led by a Dream Team of respected scientists, to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with resources to maximize human potential, including Lua`s AI-driven data and communications platform, drug development experience, and a 25,000 square foot, state-of-the-art vivarium, robotics and drug screening facility. Life Biosciences seeks to increase healthspans for everyone, including companion animals, by addressing the systemic breakdown of the body, rather than as a series of isolated symptoms and conditions.
Invitae is a leader in medical genetic testing, driving genetic information into mainstream medicine to improve healthcare for billions of people. Invitae is aggregating the world`s medical genetic tests into a single service with higher quality, faster turnaround time, and lower prices. By driving down the cost of genetic testing we make it affordable and accessible to everyone who can benefit. Why medical genetics? Within each of us lies information coded in our DNA that can transform our health. Unlocking those answers to make medicine more personalized requires highly specialized, multidisciplinary collaboration. Our platform is setting the standard for the exploding medical genetics industry by harnessing the power of advanced technologies – robotics, artificial intelligence, machine learning, software engineering – and world-class genetic expertise. We provide genetic information that guides decisions for patients facing a vast array of health questions, from ultra-rare diseases and the most common cancers to starting a family. The team driving our mission thrives in a culture designed to enable innovation at scale. We are grounded in freedom with responsibility and a universal sense of urgency and ownership. Employees are empowered to speak up, try new things and make decisions that push us forward. We provide all employees with opportunities to grow and advance, supported by flexible work hours, unlimited paid time off, the ability to work anywhere for many roles and the satisfaction of doing meaningful work. Each day at Invitae means driving forward toward a new era in which everyone can have their health decisions guided by genetics.